TransMedics Group (NASDAQ:TMDX) PT Raised to $170.00 at Piper Sandler

TransMedics Group (NASDAQ:TMDX) had its price target upped by equities researchers at Piper Sandler from $120.00 to $170.00 in a report released on Monday, Benzinga reports. The firm presently has an “overweight” rating on the stock. Piper Sandler’s price objective suggests a potential upside of 11.98% from the stock’s previous close.

Other equities analysts also recently issued reports about the company. Canaccord Genuity Group upped their price target on TransMedics Group from $102.00 to $117.00 and gave the company a “buy” rating in a report on Wednesday, May 1st. Oppenheimer increased their price objective on TransMedics Group from $105.00 to $125.00 and gave the company an “outperform” rating in a research note on Wednesday, May 1st. Cantor Fitzgerald started coverage on TransMedics Group in a research note on Thursday, June 6th. They issued an “overweight” rating and a $161.00 price objective on the stock. TD Cowen raised their target price on TransMedics Group from $130.00 to $175.00 and gave the company a “buy” rating in a report on Friday, June 7th. Finally, Stephens initiated coverage on TransMedics Group in a report on Tuesday, June 4th. They set an “overweight” rating and a $151.00 price objective on the stock. One research analyst has rated the stock with a hold rating and nine have issued a buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $146.38.

TransMedics Group Stock Performance

TMDX stock opened at $151.81 on Monday. TransMedics Group has a one year low of $36.42 and a one year high of $154.75. The company has a debt-to-equity ratio of 3.18, a quick ratio of 8.76 and a current ratio of 9.72. The firm has a market cap of $5.00 billion, a price-to-earnings ratio of -446.50 and a beta of 1.98. The firm has a 50-day simple moving average of $141.00 and a two-hundred day simple moving average of $105.37.

TransMedics Group (NASDAQ:TMDX) last issued its quarterly earnings data on Tuesday, April 30th. The company reported $0.35 EPS for the quarter, topping analysts’ consensus estimates of ($0.05) by $0.40. TransMedics Group had a negative net margin of 3.43% and a positive return on equity of 7.95%. The business had revenue of $96.90 million for the quarter, compared to analysts’ expectations of $83.78 million. During the same quarter last year, the company earned ($0.08) EPS. The business’s revenue was up 132.9% on a year-over-year basis. On average, equities analysts forecast that TransMedics Group will post 0.81 EPS for the current fiscal year.

Insider Buying and Selling

In other news, insider Tamer I. Khayal sold 63,260 shares of the stock in a transaction that occurred on Wednesday, May 1st. The stock was sold at an average price of $108.54, for a total value of $6,866,240.40. Following the completion of the transaction, the insider now directly owns 9,792 shares of the company’s stock, valued at approximately $1,062,823.68. The sale was disclosed in a legal filing with the SEC, which is available at this link. In other news, Director David Weill sold 1,193 shares of the firm’s stock in a transaction on Wednesday, May 29th. The stock was sold at an average price of $141.65, for a total value of $168,988.45. Following the transaction, the director now directly owns 10,732 shares in the company, valued at approximately $1,520,187.80. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Tamer I. Khayal sold 63,260 shares of the firm’s stock in a transaction on Wednesday, May 1st. The stock was sold at an average price of $108.54, for a total value of $6,866,240.40. Following the completion of the transaction, the insider now owns 9,792 shares in the company, valued at $1,062,823.68. The disclosure for this sale can be found here. In the last 90 days, insiders sold 239,042 shares of company stock valued at $28,835,877. Insiders own 7.00% of the company’s stock.

Institutional Trading of TransMedics Group

Institutional investors have recently modified their holdings of the company. Mackenzie Financial Corp acquired a new position in TransMedics Group during the fourth quarter worth approximately $35,804,000. Wasatch Advisors LP acquired a new position in TransMedics Group during the first quarter worth approximately $32,162,000. American Century Companies Inc. increased its position in TransMedics Group by 271.2% during the third quarter. American Century Companies Inc. now owns 486,956 shares of the company’s stock worth $26,661,000 after buying an additional 355,755 shares during the last quarter. First Turn Management LLC acquired a new position in shares of TransMedics Group in the fourth quarter valued at approximately $25,509,000. Finally, First Light Asset Management LLC grew its position in shares of TransMedics Group by 22.0% in the fourth quarter. First Light Asset Management LLC now owns 754,317 shares of the company’s stock valued at $59,538,000 after purchasing an additional 136,217 shares during the last quarter. 99.67% of the stock is currently owned by institutional investors.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.